| Schedule of computation of basic and diluted net loss per share |
The following table sets forth the computation of basic and diluted net loss per share for the three and six months ended June 30, 2026 and 2025 (in thousands, except share and per share amounts):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
For the Six Months Ended June 30, |
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Numerator |
|
|
|
|
|
|
|
|
|
|
|
Net loss |
$ |
(46,436 |
) |
|
$ |
(36,965 |
) |
|
$ |
(89,057 |
) |
|
$ |
(74,917 |
) |
Less: Net loss attributable to noncontrolling interests |
|
(18,014 |
) |
|
|
(20,413 |
) |
|
|
(40,598 |
) |
|
|
(41,631 |
) |
Net loss available to Class A common stockholders of ProKidney Corp.,
basic and diluted |
$ |
(28,422 |
) |
|
$ |
(16,552 |
) |
|
$ |
(48,459 |
) |
|
$ |
(33,286 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Denominator |
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares of Class A common stock of ProKidney Corp. outstanding,
basic and diluted |
|
186,560,999 |
|
|
|
130,730,840 |
|
|
|
164,366,352 |
|
|
|
129,858,450 |
|
Net loss per share attributable to Class A common stock |
|
|
|
|
|
|
|
|
|
|
|
Net loss per share attributable to Class A common stock of ProKidney Corp., basic and diluted |
$ |
(0.15 |
) |
|
$ |
(0.13 |
) |
|
$ |
(0.29 |
) |
|
$ |
(0.26 |
) |
Outstanding anti-dilutive securities not included in the diluted net loss per share calculation include the following:
|
|
|
|
|
|
|
|
|
As of June 30, |
|
|
2026 |
|
|
2025 |
|
Antidilutive securities |
|
|
|
|
|
ProKidney Corp. Class B common stock |
|
96,596,315 |
|
|
|
159,288,931 |
|
Unvested Restricted Stock Rights |
|
– |
|
|
|
742,684 |
|
Earnout Rights |
|
17,500,000 |
|
|
|
17,500,000 |
|
Stock options granted under the 2022 Equity Incentive Plan |
|
39,826,692 |
|
|
|
30,504,248 |
|
|